Top

Published in:

Open Access 01-04-2018 | Original Research

Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries

Authors: Martin Haluzik, Adam Kretowski, Krzysztof Strojek, Leszek Czupryniak, Andrej Janez, Peter Kempler, Michal Andel, Tsvetalina Tankova, Mihail Boyanov, Lea Smircic Duvnjak, Laszlo Madacsy, Iwona Tarnowska, Marcin Zychma, Nebojsa Lalic

Published in: Diabetes Therapy | Issue 2/2018

Abstract

Introduction

The aim of this study was to determine the level of awareness of hypoglycemia, the level of fear for hypoglycemia, and the response to hypoglycemic events among insulin-treated diabetes patients from Central and Eastern Europe (CEE). The impact of hypoglycemia on the use of healthcare resources and patient productivity was also assessed.

Methods

This was a multicenter, non-interventional, two-part, patient self-reported questionnaire study that comprised both a retrospective cross-sectional evaluation and a prospective observational evaluation. Study participants were insulin-treated adult patients with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) from CEE.

Results

Most patients (85.4% T1DM and 83.6% T2DM) reported normal hypoglycemia awareness. The median hypoglycemia fear score was 5 out of 10 for T1DM and 4 out of 10 for T2DM patients. Patients increased glucose monitoring, consulted a doctor/nurse, and/or reduced the insulin dose in response to hypoglycemia. As a consequence of hypoglycemia, patients took leave from work/studies or arrived late and/or left early. Hospitalization was required for 31 (1.2%) patients with T1DM and 66 (2.1%) patients with T2DM.

Conclusion

Hypoglycemia impacts patients’ personal and social functioning, reduces productivity, and results in additional costs, both direct (related to increased use of healthcare resources) and indirect (related to absenteeism.

Funding

Novo Nordisk.

American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40[Suppl 1]:S1–135.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59. https://doi.org/10.1056/NEJMoa0802743.CrossRef

Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycaemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–8. https://doi.org/10.1056/NEJMoa1003795.CrossRefPubMed

Desouza CV, Bolli GB, Fonseca V. Hypoglycaemia, diabetes and cardiovascular events. Diabetes Care. 2010;33(6):1389–94. https://doi.org/10.2337/dc09-2082.CrossRefPubMedPubMedCentral

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.CrossRefPubMed

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827.CrossRefPubMedPubMedCentral

Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycaemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173(14):1300–6. https://doi.org/10.1001/jamainternmed.2013.6176.CrossRefPubMedPubMedCentral

Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab. 2008;10[Suppl 1]:16–24. https://doi.org/10.1111/j.1463-1326.2008.00883.x.CrossRefPubMed

Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev. 2008;24(2):87–92. https://doi.org/10.1002/dmrr.796.CrossRefPubMed

10.

Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384–95. https://doi.org/10.2337/dc12-2480.CrossRefPubMedPubMedCentral

11.

Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med. 2014;31(1):92–101. https://doi.org/10.1111/dme.12261.CrossRefPubMed

12.

Kenny C. When hypoglycemia is not obvious: diagnosing and treating under-recognized and undisclosed hypoglycemia. Prim Care Diabetes. 2014;8(1):3–11. https://doi.org/10.1016/j.pcd.2013.09.002.CrossRefPubMed

13.

Khunti K, Alsifri S, Aronson R, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907–15. https://doi.org/10.1111/dom.12689.CrossRefPubMedPubMedCentral

14.

Brath H, Paldánius PM, Bader G, Kolaczynski WM, Nilsson PM. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy. Nutr Diabetes. 2016;6(7):e217M. https://doi.org/10.1038/nutd.2016.25.CrossRef

15.

American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38[Suppl 1]:S1–93.

16.

Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245–9.CrossRef

17.

Wohland T, Holstein JD, Patzer OM, et al. New risk and protective factors for severe hypoglycaemia in people with type 1 diabetes. Nutr Metab Cardiovasc Dis. 2017;27(5):407–14. https://doi.org/10.1016/j.numecd.2016.12.006.

18.

Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med. 2008;25(4):501–4. https://doi.org/10.1111/j.1464-5491.2008.02413.x.CrossRefPubMed

19.

Hendrieckx C, Hagger V, Jenkins A, Skinner TC, Pouwer F, Speight J. Severe hypoglycemia, impaired awareness of hypoglycemia, and self-monitoring in adults with type 1 diabetes: results from Diabetes MILES-Australia. J Diabetes Complications. 2017;31(3):577–82. https://doi.org/10.1016/j.jdiacomp.2016.11.013.CrossRefPubMed

20.

Weitgasser R, Lopes S. Self-reported frequency and impact of hypoglycaemic events in insulin-treated diabetic patients in Austria. Wien Klin Wochenschr. 2015;127(1–2):36–44. https://doi.org/10.1007/s00508-014-0626-1.CrossRefPubMed

21.

Peene B, D’Hooge D, Vandebrouck T, Mathieu C. Patient-reported frequency, awareness and patient-physician communication of hypoglycaemia in Belgium. Acta Clin Belg. 2014;69(6):439–45. https://doi.org/10.1179/2295333714Y.0000000050.CrossRefPubMed

22.

Kulzer B, Seitz L, Kern W. Real-world patient-reported rates of non-severe hypoglycaemic events in Germany. Exp Clin Endocrinol Diabetes. 2014;122(3):167–72. https://doi.org/10.1055/s-0033-1363688.CrossRefPubMed

23.

Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract. 2010;87(1):64–8. https://doi.org/10.1016/j.diabres.2009.10.013.CrossRefPubMed

24.

Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes-more common than you think: a continuous glucose monitoring study. J Diabetes Sci Technol. 2015;9(5):999–1005. https://doi.org/10.1177/1932296815581052.CrossRefPubMedPubMedCentral

25.

Büyükkaya Besen D, Arda Sürücü H, Koşar C. Self-reported frequency, severity of, and awareness of hypoglycemia in type 2 diabetes patients in Turkey. PeerJ. 2016;4:e2700. https://doi.org/10.7717/peerj.2700.CrossRefPubMedPubMedCentral

26.

Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev. 2003;19(3):232–40. https://doi.org/10.1002/dmrr.377.CrossRefPubMed

27.

Martyn-Nemeth P, Quinn L, Penckofer S, Park C, Hofer V, Burke L. Fear of hypoglycemia: influence on glycemic variability and self-management behavior in young adults with type 1 diabetes. J Diabetes Complications. 2017;31(4):735–41. https://doi.org/10.1016/j.jdiacomp.2016.12.015.CrossRefPubMed

28.

Strandberg RB, Graue M, Wentzel-Larsen T, Peyrot M, Wahl AK, Rokne B. The relationships among fear of hypoglycaemia, diabetes-related quality of life and psychological well-being in Norwegian adults with Type 1 diabetes. Diabetes Res Clin Pract. 2017;124:11–9. https://doi.org/10.1016/j.diabres.2016.12.018.CrossRefPubMed

29.

Lopez JM, Annunziata K, Bailey RA, Rupnow MF, Morisky DE. Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence. Patient Prefer Adherence. 2014;8:683–92. https://doi.org/10.2147/PPA.S58813.CrossRefPubMedPubMedCentral

30.

Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med. 2012;124(1):124–32. https://doi.org/10.3810/pgm.2012.01.2525.CrossRefPubMed

31.

Fulcher G, Singer J, Castañeda R, et al. The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. J Med Econ. 2014;17(10):751–61. https://doi.org/10.3111/13696998.2014.946992.CrossRefPubMed

32.

Brod M, Wolden M, Groleau D, Bushnell DM. Understanding the economic, daily functioning, and diabetes management burden of non-severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2. J Med Econ. 2014;17(1):11–20. https://doi.org/10.3111/13696998.2013.857676.CrossRefPubMed

33.

Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, Lahtela J, Jensen MM, Östenson CG. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ. 2013;16(12):1453–61. https://doi.org/10.3111/13696998.2013.852098.CrossRefPubMed

34.

Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14(5):646–55. https://doi.org/10.3111/13696998.2011.610852.CrossRefPubMed

35.

Widz K, Czech M, Hermanowski T. Cost of hypoglycaemia in patients with diabetes in Poland. PHS49. Value Health. 2012;15:A277–575. https://doi.org/10.1016/j.jval.2012.08.1822.CrossRef

36.

Goldstein D, Chodick G, Shalev V, Thorsted BL, Elliott L, Karasik A. Use of healthcare services following severe hypoglycemia in patients with diabetes: analysis of real-world data. Diabetes Ther. 2016;7(2):295–308. https://doi.org/10.1007/s13300-016-0169-8.CrossRefPubMedPubMedCentral

37.

Jakubczyk M, Lipka I, Pawęska J, et al. Cost of severe hypoglycaemia in nine European countries. J Med Econ. 2016;19(10):973–82. https://doi.org/10.1080/13696998.2016.1188823.CrossRefPubMed

38.

Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res. 2011;2(4):137–44. https://doi.org/10.4103/2229-3485.86879.CrossRefPubMedPubMedCentral

Title: Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries
Authors: Martin Haluzik
Adam Kretowski
Krzysztof Strojek
Leszek Czupryniak
Andrej Janez
Peter Kempler
Michal Andel
Tsvetalina Tankova
Mihail Boyanov
Lea Smircic Duvnjak
Laszlo Madacsy
Iwona Tarnowska
Marcin Zychma
Nebojsa Lalic
Publication date: 01-04-2018
Publisher: Springer Healthcare
Published in: Diabetes Therapy / Issue 2/2018
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-018-0388-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Funding

Please log in to get access to this content

Other articles of this Issue 2/2018

Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment

User Performance Evaluation of Four Blood Glucose Monitoring Systems Applying ISO 15197:2013 Accuracy Criteria and Calculation of Insulin Dosing Errors

Factors That Influence Pancreatic Beta Cell Function and Insulin Resistance in Newly Diagnosed Type 2 Diabetes Patients: A Sub-Analysis of the MARCH Trial

Changing Patients’ Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes

A Real-World Anti-Diabetes Medication Cost Comparison Between Premixed Insulin Analogs and Long-Acting Insulin Analogs in Chinese Patients with Type 2 Diabetes: A Retrospective Database Analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials